The U.S. Food and Drug Administration (U.S. FDA) has authorised Granules India’s abbreviated new drug utility for hypertension drug Metoprolol Succinate Extended-Release Tablets USP, 25 mg, 50 mg, 100 mg and 200 mg.
The product is bioequivalent to Toprol-XL Tablets, 25 mg, 50 mg, 100 mg and 200 mg, of Toprol Acquisition LLC, the reference listed drug.
Metoprolol Succinate ER tablets are indicated to decrease blood strain and their annual U.S. market is about $321 million, Granules stated citing MAT March 2023 IQVIA/IMS Health numbers. The firm now has 57 ANDA approvals from U.S. FDA (55 last approvals and two tentative approvals. On Tuesday, Granules shares closed 2.26% larger at ₹285.55 every on the BSE.
